Cargando…
Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862549/ https://www.ncbi.nlm.nih.gov/pubmed/29576629 http://dx.doi.org/10.1055/s-0044-101613 |
_version_ | 1783308246243606528 |
---|---|
author | Taran, Florin-Andrei Schneeweiss, Andreas Lux, Michael P. Janni, Wolfgang Hartkopf, Andreas D. Nabieva, Naiba Overkamp, Friedrich Kolberg, Hans-Christian Hadji, Peyman Tesch, Hans Wöckel, Achim Ettl, Johannes Lüftner, Diana Wallwiener, Markus Müller, Volkmar Beckmann, Matthias W. Belleville, Erik Wallwiener, Diethelm Brucker, Sara Y. Fasching, Peter A. Fehm, Tanja N. Schütz, Florian |
author_facet | Taran, Florin-Andrei Schneeweiss, Andreas Lux, Michael P. Janni, Wolfgang Hartkopf, Andreas D. Nabieva, Naiba Overkamp, Friedrich Kolberg, Hans-Christian Hadji, Peyman Tesch, Hans Wöckel, Achim Ettl, Johannes Lüftner, Diana Wallwiener, Markus Müller, Volkmar Beckmann, Matthias W. Belleville, Erik Wallwiener, Diethelm Brucker, Sara Y. Fasching, Peter A. Fehm, Tanja N. Schütz, Florian |
author_sort | Taran, Florin-Andrei |
collection | PubMed |
description | This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects. |
format | Online Article Text |
id | pubmed-5862549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-58625492018-03-23 Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers Taran, Florin-Andrei Schneeweiss, Andreas Lux, Michael P. Janni, Wolfgang Hartkopf, Andreas D. Nabieva, Naiba Overkamp, Friedrich Kolberg, Hans-Christian Hadji, Peyman Tesch, Hans Wöckel, Achim Ettl, Johannes Lüftner, Diana Wallwiener, Markus Müller, Volkmar Beckmann, Matthias W. Belleville, Erik Wallwiener, Diethelm Brucker, Sara Y. Fasching, Peter A. Fehm, Tanja N. Schütz, Florian Geburtshilfe Frauenheilkd This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects. Georg Thieme Verlag KG 2018-03 2018-03-21 /pmc/articles/PMC5862549/ /pubmed/29576629 http://dx.doi.org/10.1055/s-0044-101613 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Taran, Florin-Andrei Schneeweiss, Andreas Lux, Michael P. Janni, Wolfgang Hartkopf, Andreas D. Nabieva, Naiba Overkamp, Friedrich Kolberg, Hans-Christian Hadji, Peyman Tesch, Hans Wöckel, Achim Ettl, Johannes Lüftner, Diana Wallwiener, Markus Müller, Volkmar Beckmann, Matthias W. Belleville, Erik Wallwiener, Diethelm Brucker, Sara Y. Fasching, Peter A. Fehm, Tanja N. Schütz, Florian Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers |
title | Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers |
title_full | Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers |
title_fullStr | Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers |
title_full_unstemmed | Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers |
title_short | Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers |
title_sort | update breast cancer 2018 (part 1) – primary breast cancer and biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862549/ https://www.ncbi.nlm.nih.gov/pubmed/29576629 http://dx.doi.org/10.1055/s-0044-101613 |
work_keys_str_mv | AT taranflorinandrei updatebreastcancer2018part1primarybreastcancerandbiomarkers AT schneeweissandreas updatebreastcancer2018part1primarybreastcancerandbiomarkers AT luxmichaelp updatebreastcancer2018part1primarybreastcancerandbiomarkers AT janniwolfgang updatebreastcancer2018part1primarybreastcancerandbiomarkers AT hartkopfandreasd updatebreastcancer2018part1primarybreastcancerandbiomarkers AT nabievanaiba updatebreastcancer2018part1primarybreastcancerandbiomarkers AT overkampfriedrich updatebreastcancer2018part1primarybreastcancerandbiomarkers AT kolberghanschristian updatebreastcancer2018part1primarybreastcancerandbiomarkers AT hadjipeyman updatebreastcancer2018part1primarybreastcancerandbiomarkers AT teschhans updatebreastcancer2018part1primarybreastcancerandbiomarkers AT wockelachim updatebreastcancer2018part1primarybreastcancerandbiomarkers AT ettljohannes updatebreastcancer2018part1primarybreastcancerandbiomarkers AT luftnerdiana updatebreastcancer2018part1primarybreastcancerandbiomarkers AT wallwienermarkus updatebreastcancer2018part1primarybreastcancerandbiomarkers AT mullervolkmar updatebreastcancer2018part1primarybreastcancerandbiomarkers AT beckmannmatthiasw updatebreastcancer2018part1primarybreastcancerandbiomarkers AT bellevilleerik updatebreastcancer2018part1primarybreastcancerandbiomarkers AT wallwienerdiethelm updatebreastcancer2018part1primarybreastcancerandbiomarkers AT bruckersaray updatebreastcancer2018part1primarybreastcancerandbiomarkers AT faschingpetera updatebreastcancer2018part1primarybreastcancerandbiomarkers AT fehmtanjan updatebreastcancer2018part1primarybreastcancerandbiomarkers AT schutzflorian updatebreastcancer2018part1primarybreastcancerandbiomarkers |